论文部分内容阅读
目的观察消积饮联合化疗治疗晚期非小细胞肺癌(NSCLC)对循环血管内皮细胞(CECs)和血管内皮生长因子(VEGF)表达调控的影响及其近期疗效,以探讨CECs及VEGF作为评价消积饮治疗晚期NSCLC的抗血管生成作用的临床应用价值。方法 50例晚期NSCLC患者,随机分为试验组和治疗组。试验组给予消积饮联合TP方案化疗治疗,对照组给予单纯TP方案化疗治疗,首要观察指标两组CECs的表型(CD146+)及VEGF的数量变化,次要观察指标包括近期疗效的客观应答率(ORR)和毒副反应。结果首要观察指标CD146+值治疗后试验组(0.76±0.35)明显低于对照组(1.93±2.39),具统计学差异(P<0.05);另一首要观察指标VEGF值治疗后试验组(159.67±93.14)低于对照组(218.99±113.76),具统计学差异(P=0.049<0.05)。次要观察指标,ORR治疗后试验组为40.0%(10例),对照组为20.0%(5例),无统计学意义(P>0.05)。两组均无严重不良反应及毒副反应。结论 CECs、VEGF均可用于评估中药消积饮治疗晚期NSCLC抗血管生成作用,尤以CECs为佳。
Objective To observe the effect of Xiaoyin Decoction combined with chemotherapy on the treatment of advanced non-small cell lung cancer (NSCLC) on the expression of circulating vascular endothelial cells (CECs) and vascular endothelial growth factor (VEGF) Clinical application of anti-angiogenesis in the treatment of advanced non-small cell lung cancer. Methods Fifty patients with advanced NSCLC were randomly divided into experimental group and treatment group. The experimental group was given Xiajiangyin combined with TP regimen chemotherapy, while the control group was given TP regimen chemotherapy. The primary observation index was the change of the phenotype of CECs (CD146 +) and the number of VEGF in the two groups. The subjective indexes included the objective response rate (ORR) and toxic side effects. Results The primary observation index CD146 + value in the test group (0.76 ± 0.35) was significantly lower than that in the control group (1.93 ± 2.39), with statistical difference (P <0.05); the other primary observation index VEGF value in the test group (159.67 ± 93.14) was lower than the control group (218.99 ± 113.76), with statistical difference (P = 0.049 <0.05). The secondary outcome measures were 40.0% (10 cases) in the trial group and 20.0% (5 cases) in the control group after ORR treatment, with no significant difference (P> 0.05). No serious adverse reactions and side effects were observed in both groups. Conclusion Both CECs and VEGF can be used to evaluate the anti-angiogenic effect of Xiaoji Decoction in advanced NSCLC, especially CECs.